---

Nifedipine versus magnesium sulfate in the management of preterm labour- A randomised controlled trial

---

Original Article

Author Details : Shalini Bhat, Apoorva Jain, Sunil K S*

Volume : 10, Issue : 4, Year : 2023

Article Page : 460-468

https://doi.org/10.18231/j.ijogr.2023.088

Suggest article by email

Get Permission

---

Abstract

Background: Preterm labour is the leading cause of perinatal morbidity and mortality worldwide. Preterm birth accounts for 75% of neonatal deaths and 50% of long-term morbidity including respiratory disease and neuro-developmental impairment. The use of tocolysis in women in preterm labour aims to inhibit uterine contractions and reduce perinatal morbidity and mortality associated with early delivery.
Aim: To study the effect and compare the efficacy of Nifedipine and Magnesium sulphate in management of preterm labour.
Materials and Methods: This randomized controlled trial was performed on 80 women with preterm labor between 28 and 37 weeks of gestation who were randomly assigned to receive either MgSO4 or nifedipine. All patients were checked for successful prolongation of pregnancy who had not been delivered at 48 hours [primary tocolytics effects] and more than 7 days [secondary tocolytics effects] after beginning the treatment and side effects of tocolysis.
Results: From 80 patients, 40 received nifedipine and 40 received MgSO4. There were no differences in suppression of labor pain in 24 hours, 48 hours and 7 days between the two groups. Even though there were no statistically significant differences in one-minute and five-minute Apgar scores, neonatal respiratory distress syndrome between the groups neonates of MgSO4 group had more NICU admission which is significant (p value 0.049).
Conclusion: Oral nifedipine is as effective as magnesium sulfate with regard to inhibition of preterm labor.
 

Keywords: Preterm labour, Tocolytics, Random controlled trial.

How to cite : Bhat S, Jain A, Sunil K S, Nifedipine versus magnesium sulfate in the management of preterm labour- A randomised controlled trial. Indian J Obstet Gynecol Res 2023;10(4):460-468

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.